406 results about "Pharmaceutical Adjuvants" patented technology

A method for extracting hyperin comprises the following steps: a crude product of an extracting solution of a maniod eibish flower is obtained through extracting the concentrated solution of a maniod eibish flow ethanol extracting solution by normal butanol or ethyl acetate or through the column chromatography of an HPD100 or HPD600 macroscopic absorbent resin; and then hyperin with the content of between 90 and 98 percent in weight percentage is obtained through purification and recrystallization by using a solvent. Hyperin preparations comprise freeze-dried powder injection, liquid drugs injection, transfusions, dropped pills, tablets, capsules, or soft capsules prepared by using hyperin as an active component and pharmaceutical adjuvant. The hyperin is used for preparing the medicines for treating cerebral ischemia.

The invention provides a plant cellulose hard empty capsule preparation method, and belongs to the technical field of pharmaceutical adjuvants. The plant cellulose is obtained from plant derivatives such as pine trees, purified cotton and the like. Prepared plant cellulose hard empty capsules comprise colorless and transparent hard empty capsules, colored hard empty capsules and light-shielding hard empty capsules. The preparation method comprises steps of: mixing the plant cellulose, a surfactant, a coagulant aid, a coloring agent and water, forming and drying. The plant cellulose hard empty capsule has performance stability, low water content and no interference with human body metabolism, and is green, environment-friendly, safe and suitable for being filled with various contents.

A cinobufotalin freeze dried injection and preparation process thereof are disclosed. It is prepared by cinobufotalin effective part and pharmaceutical adjuvant extracted from dry toad skin. The effective part of cinobufotalin is obtained by alcohol extraction, centrifugation and macropore polymeric adsorbent separation and purification. Wherein, the main effective component indole total alkaloid content is over than 30%. The content assay result and pharmaceutical examination result indicates that the cinobufotalin freeze dried injection has a higher content of effective part and stronger pharmaceutical function.

The invention discloses a sustained release tablet of a quetiapine fumarate composition, comprising the following components in percentage by weight: 25 to 40% of quetiapine fumarate, 2 to 8% of organic acid salt, 5 to 30% of a sustained release material and the balance of other pharmaceutical adjuvants, wherein the sustained release material is K type hydroxypropyl methylcellulose. The sustained release material is the K type hydroxypropyl methylcellulose and the organic acid salt is added, therefore, a stable sustained release skeleton can be formed by few sustained release materials, the raw material can be saved, the weight of unit preparation can be reduced, and the problem of difficulty in swallowing caused by large size of the preparation can be released and/or solved; the hydroxypropyl methylcellulose with different viscosities are used as the material of the skeleton so that the preparation can reach formulated sustained release effects and has the characteristics of strong controllability and stability in storage. By use of the preparation method capable of granulating in one step, the operation is simplified and the production efficiency can be improved.

The invention provides a Chinese medicinal composition for treating digestive system diseases, which is mainly prepared from Chinese medicinal materials such as phellodendron, spreading hedyotis herb, dried ginger, seabuckthorn and the like according to a certain weight ratio. The Chinese medicinal composition can be prepared into any common oral preparation with appropriate pharmaceutical adjuvants according to the conventional preparation process. The Chinese medicinal composition has the effects of clearing heat and detoxicating and subdhing swelling and stopping ulcer. Clinical observation indicates that the Chinese medicinal composition can be widely used for treating the digestive system diseases, and particularly has a good treatment effect on peptic ulcer.

The invention discloses an enzalutamide soft capsule and a preparation method thereof. The enzalutamide soft capsule comprises capsule content and a capsule shell, wherein the capsule content comprises enzalutamide and pharmaceutical adjuvants; the capsule shell is formed by gelatin, glycerin, sorbitol, titanium dioxide, purified water and the like. The soft capsule can be prepared with the method comprising following steps: Labrasol, butylated hydroxyanisole, butylated hydroxytoluene and enzalutamide are mixed to obtain the capsule content material of the soft capsule; the gelatin, the glycerin, the sorbitol, titanium dioxide and the purified water are mixed to obtain the capsule shell material of the soft capsule; the capsule content material and the capsule shell material of the soft capsule are pelleted on a soft capsule making machine to obtain the enzalutamide soft capsule. The enzalutamide soft capsule and the preparation method have the following advantages: the soft capsule is convenient to administrate and carry, the drug stability is good, effective components are dissolved quickly, and the bioavailability is high.

The invention discloses a preparation method for extracting ethanol from an extract of a natural walnut shell, a pharmaceutical composition using the extract as the active component and research results of relevant pharmacology. A walnut shell is ground and boiled for extracting the ethanol and then is concentrated and dried for obtaining the brown red extract. The extracting method is characterized by short process, relatively high extracting rate and is easy for industrialized production. The discovery of the medical value of the walnut shell and the development of the product can prevent great waste of natural pharmaceutical resources. The research of the pharmacological activity shows that the walnut shell extract has a certain activity for strengthening heart and improving myocardial blood supply and is possible to be developed into a new pharmaceutical of natural traditional Chinese medicine for curing cardio-cerebrovascular disease, having a plurality of pharmacological activities, low toxicity and high efficiency. Various oral preparations of different pharmaceutical compositions can be prepared by mixing the extract of effective curing amount with pharmaceutical adjuvant.

The invention relates to swelling reducing and pain easing gel and preparation method thereof. The gel mainly contains swelling reducing and pain easing tincture liquid medicine, gel substrate and other pharmaceutical adjuvant and has the characteristics of small dosage of the adjuvant and good stability. The gel acts locally, has the functions of stimulating blood circulation and causing the muscles and joints to relax, reducing swelling and easing pain, and is used for curing injuries from falls, rheumatism, unknown swelling and toxin, and parotitis swelling. The gel has the advantages of long dwell time, durable effect, simple formulation process, low production cost and strong operability in industrial production.

The invention discloses a sildenafil citrate sublingual tablet and a preparation method thereof. The sildenafil citrate sublingual tablet is prepared from 1 part by weight of sildenafil citrate and 4 to 8 parts by weight of pharmaceutical adjuvant , wherein the pharmaceutical adjuvant comprises 2 to 4 percent of disintegrant, 94 to 96 percent of diluter, 0.5 to 1.2 percent of lubricator, 0.3 to 1 percent of corrective and 0.1 to 0.2 percent of binder, which are based on the total weight of the pharmaceutical adjuvant. Test results show that the prepared sublingual tablet has shorter disintegration time, higher dissolving speed in vitro and higher body bioavailability than the conventional tablets.

The invention discloses a pharmaceutical adjuvant automatic production line control system and relates to the field of pharmaceutical adjuvant production. The system comprises production data acquisition and analysis, production equipment operation state monitoring, key process intelligent quality detection, product information management, and automatic identification technical facility and automatic logistics equipment use; according to the production data acquisition and analysis, a production plan is automatically generated according to the content of a sales plan. According to the system of the invention, overall control is carried out based on the automatic production line control system; a production plan is automatically generated according to the sales plan and issued to a workshopcentral control system; the central control system plans a and deploys a production line; equipment operation states are collected in real time and fed back to the central control system; the centralcontrol system performs analysis and then processes the information and sends a result to each terminal; production conditions are collected and transmitted to the central control system in real timein a production process; an alarm is automatically given when reaction parameters deviate from a set standard; automatic or manual adjustment is performed in a PLC system to perform exception removal; and therefore, the real-time feedback rate can be increased, production quality can be controlled more easily, and production efficiency can be improved.

The invention discloses a method for preparing total ginkgo flavone glycosides slow-release capsules by applying attapulgite, which comprises the following steps of: washing, drying and pulverizing gingko leaves into coarse powder; adding the gingko leaf coarse powder and petroleum ether with the weight ten times of the gingko leaf coarse powder into a container, refluxing and extracting for 1 hour, degreasing, filtering and drying; adding water with the weight ten times of the degreased gingko leaf coarse powder into the degreased gingko leaf coarse powder, boiling, decocting for 3 times, combining decocting liquids, filtering and concentrating to the relative density of 1.10; adding ethanol with the mass concentration of 95 percent into a concentrated liquid until the ethanol concentration is 70 percent, depositing, settling and filtering; adsorbing a filtrate through modified attapulgite to obtain the attapulgite loading total ginkgo flavone glycosides; and adding a pharmaceutical adjuvant material into the attapulgite loading total ginkgo flavone glycosides, and encapsulating into empty capsules to obtain the total ginkgo flavone glycosides slow-release capsules. The invention adopts the principle of adsorption separation and selects the modified attapulgite with strong adsorbability for the total ginkgo flavone glycosides to directly prepare a preparation without elution, the total ginkgo flavone glycosides slow-release capsules are slowly desorbed under the desorption action of a body fluid, steps are simplified, the production period is shortened, and the yield of products is improved.

The invention discloses kelp microcrystalline cellulose and a preparation method thereof as well as application of the prepared microcrystalline cellulose. The preparation method of the kelp microcrystalline cellulose comprises the following steps of by adopting waste kelp residues after kelp glue-extracting as the materials, carrying out flocculation collecting, acidification decalcification, alkaline treatment, bleaching treatment, washing, drying and hydrolytic treatment, wherein in the hydrolytic treatment, two different low-temperature cellulases are respectively added according to the addition of 20U/g-30U/g; carrying out enzymolysis for 0.5-12 hours in a water bath of 10 DEG C-40 DEG C; and drying and crushing to obtain the kelp microcrystalline cellulose. According to the preparation method of the kelp microcrystalline cellulose, the production cost is low, the environment pollution is small, the hydrolysis step adopts a double-enzyme jointed enzymolysis technology, the degradation speed is stable, the degraded cellulose is uniform in molecular weight, the cellulose crystalline grains are small and uniform, degradability of the fibers can be effectively controlled, and the microcrystalline cellulose with high purity and high activity is obtained. The kelp microcrystalline cellulose disclosed by the invention is high in cellulose content, high in water holding capacity and expansion force, and can be used for food additive and pharmaceutical adjuvant in the food industry.

The invention provides a preparation method of pharmaceutical adjuvant sodium carboxymethyl starch. The preparation method comprises the following chemical reactions: carrying out etherification reaction on starch and sodium hydroxide solution, after the reaction, washing and centrifugally separating so as to obtain the qualified sodium carboxymethyl starch, wherein the washing process is used for desalting. The preparation method provided by the invention has the advantages that the step is simple and reasonable, and the cost of the obtained pharmaceutical adjuvant sodium carboxymethyl starch is lower. The obtained sodium carboxymethyl starch is dried under 75 DEG C-95 DEG C so as to obtain the product with the qualified water content, and then the product is pulverized and sieved, and is introduced into a weighing and packaging process. The main component of the supernatant liquid, washing liquid and filtered solution generated in the processing step is ethanol and ethanol can be recycled by a fractionating tower.

The invention belongs to the technical field of medicaments and relates to a furan derivative and application thereof, in particular to a new furan derivative for treating immunologic diseases. The structural formula of the furan derivative is shown in the specifications, wherein an R group can be linear chain alkyl and branched chain alkyl having 2 to 11 carbon atoms. A compound has a stable structure and various clinically acceptable formulations can be prepared by matching the compound with an appropriate amount of pharmaceutical adjuvant. An immunology experimental result indicates that the compound has relatively high anti-complement activity and no activity difference between two formulations, so the compound has the advantages of relatively high activity, little medicament dosage and the like. The furan derivative and a preparation which is possibly developed by the furan derivative are mainly used for treating various diseases caused by over activation of a complement system. The R group is linear chain alkyl and branched chain alkyl having 2 to 11 carbon atoms.

The invention relates to a preparation method of a cross-linking sodium carboxymethylcellulose pharmaceutical adjuvant. The method comprises the following steps: firstly, adjusting the pH value of a dispersion liquid of sodium carboxymethylcellulose with degree of substitution of 0.65-0.80 by a degree of substitution adjusting system to 10-14; continuously stirring till the system is uniformly dispersed; then, stirring and adding an ethanol liquid of epoxy chloropropane as a cross-linking agent, wherein epoxy chloropropane in the ethanol liquid of epoxy chloropropane accounts for 6-40wt% of ethanol liquid of epoxy chloropropane; stirring at 10-60 DEG C and reacting for 2-12 hours; after reaction, adding acid to neutralize; filtering, washing and drying; and smashing and sieving to obtain the cross-linking sodium carboxymethylcellulose, wherein the physicochemical properties of the cross-linking sodium carboxymethylcellulose meet the Chinese pharmacopoeia (2) (2010 Edition). The reaction condition is mild, the degree of crosslinking is controllable, the reaction solvent is mild, and no residual organic solvents are left after reaction. In cross-linking reaction under a cross-linking reaction, sodium carboxymethylcellulose is prevented from being hydrolyzed.

The invention provides an esomeprazole pharmaceutical composition with stronger acid resistance and a preparation thereof. The esomeprazole pharmaceutical composition comprises esomeprazole, one or more antacids and common pharmaceutical adjuvants, wherein the esomeprazole comprises esomeprazole salt, particularly esomeprazole magnesium salt and esomeprazole lithium salt; and the antacids comprise sodium bicarbonate, sodium carbonate, potassium carbonate, potassium bicarbonate, calcium carbonate, aluminum carbonate, magnesium carbonate, magnesium hydroxide, magnesium oxide, aluminium hydroxide, magnesium aluminum carbonate and the like. The preparation of the esomeprazole pharmaceutical composition is prepared by adding the antacids via interior addition and exterior addition; and in an optimized preparation method, the weight ratio of the antacids in the interior addition and the exterior addition is 2: 3, so that the antacids play double efficacies, the dosage of acid neutralization agent is reduced and the acid resisting effect is better.

The invention relates to a traditional Chinese medicine combination capable of ventilating the lung, relieving exterior syndrome, relieving cough and reducing sputum, composed of hogfennel root, radix trichosanthis, peppermint, mulberry bark, bitter almond (fried), perilla seed, balloonflower, purple common perilla, glycyrrhiza, inula flower, citrus aurtantium, pummelo pee, Chinese radish seed, scullcap, pumice (calcinied) and an amount of pharmaceutical adjuvant, wherein the hogfennel root is capable of relieving cough and eliminating sputum, the mulberry bark is capable of clearing away the lung-heat and sputum, the Chinese radish seed, purple common perilla, citrus aurtantium, perilla seed, pumice, bitter almond, pummelo pee are capable of eliminating sputum and clearing away the heat-evil, the balloonflower, glycyrrhiza and inula flower are capable of regulating vital energy and eliminating sputum. The scullcap is capable of clearing away lung-heat. The peppermint is capable of dispelling wind and heat from the body, relieving the sore-throat, clearing away the head and eyes. The traditional Chinese medicine combination(Xiao'er qingfeiwan) is capable of ventilating the lung, relieving exterior syndrome, relieving cough and reducing sputum and mainly treats acute tracheitis, wind-heat type common cold, cough, white sticky sputum or yellow thick sputum. The traditional Chinese medicine combination has features of convenient administration, small dose, no side-effect and is much friendly for children.

The invention provides a preparation method for high-purity breviscapine extract as well as preparations and application thereof. The method disclosed by the invention comprises the following steps: taking erigeron breviscapus as a raw material, performing dynamic ultrasonic countercurrent extraction or heating reflux extraction, filtering, centrifuging, adjusting the pH value to 2.0-7.0, performing macroporous resin column chromatography, preparing by using dynamic axial compression industrial chromatographic separation, or preparing by adopting high-speed counter-current chromatography, freezing or performing spray drying, thereby obtaining the high-purity breviscapine extract. According to the method disclosed by the invention, extraction can be completed in a short time at a low temperature, the separation cycle is short, the efficiency is high, the occupied volume for extraction is reduced, the production cost is lowered, the energy consumption and environmental pollution can be reduced, and the purity of the obtained breviscapine can be 95% or higher. Added with various added pharmaceutical adjuvants, the high-purity breviscapine extract can be prepared into ordinary tablets, thin membrane coated tablets, capsules, dispersible tablets, dropping pills, granules, sustained-release preparations and other solid oral preparations, as well as spray, aerosol, lyophilized powder for injection and injection, and the preparations can be used for treating cardiovascular and cerebrovascular diseases and are obvious in curative effects, safe and reliable.

The invention provides a compound preparation for treating II type diabetes mellitus and a preparation method of the compound preparation. The pharmaceutical composition for treating II type diabetes mellitus is prepared from active components ipragliflozin and metformin hydrochloride as well as pharmaceutical adjuvants including a filler, an adhesive, a disintegrant and a lubricant. The compound preparation for treating II type diabetes mellitus prepared by the method has no special requirements on particle sizes of the active components, is free of superfine grinding, low in energy consumption, high in dissolution rate and high in bioavailability, and has a market development prospect; and the defects of poor dissolution rate and low bioavailability of the active components are solved.

The invention provides a metformin hydrochloride sustained-release tablet and a preparation method thereof, and belongs to the field of pharmacy. The metformin hydrochloride sustained-release tablet comprises metformin hydrochloride, a binding agent, an absorption accelerant, hydroxypropyl methylcellulose and a pharmaceutical adjuvant. The weight ratio of the metformin hydrochloride, the binding agent and the absorption accelerant is 500:(45-55):(2.5-3.5). The preparation method of the sustained-release tablet includes the steps: mixing and palletizing the absorption accelerant, the metformin hydrochloride and the binding agent; mixing palletized materials, the hydroxypropyl methylcellulose and the pharmaceutical adjuvant; pressing the mixture to obtain the metformin hydrochloride sustained-release tablet. The sustained-release tablet can widen absorbing windows of the metformin hydrochloride is high in bioavailability, blood concentration of the metformin hydrochloride can be maintained at treatment level in long time, and diseases are effectively treated. According to the method, the hydroxypropyl methylcellulose is added after palletizing, the sustained-release performance of the sustained-release tablet is greatly improved, and better treatment effects are achieved.

The invention relates to a stable medicament for oral administration which comprises (a) a core which contains an active ingredient selected from Omeprazole, Lansoprazole and Pantoprazole, together with customary pharmaceutical adjuvants, (b) an intermediate layer applied onto the core, and (c) a gastric juice-resistant outer layer. The intermediate layer in (b) is formed as a reactive layer in which a gastric juice-resistant polymer layer material partially neutralized with alkali with cation exchange capacity is present. Further, a method for the production of the stable medicament is disclosed.